Longevity Peptides 2026: Epithalon, MOTS-C, Humanin and the Science of Aging

Longevity research has shifted from broad caloric restriction studies toward targeted molecular interventions, with peptides emerging as a distinct compound class alongside small molecules and gene therapies. Three peptide families dominate current investigation: synthetic telomerase modulators (Epithalon), mitochondrial-derived peptides (MOTS-C, Humanin, SHLP family), and peptides intersecting NAD+ metabolism. Each operates through fundamentally different mechanisms, yet they converge on cellular hallmarks of aging — telomere attrition, mitochondrial dysfunction, and metabolic decline.

Epithalon (epitalon, epithalone) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly, MW 390.35 Da) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is the synthetic analog of epithalamin, a polypeptide extract from the pineal gland. Epithalon research centers on its ability to activate telomerase — the ribonucleoprotein enzyme that maintains telomere length by adding TTAGGG repeats to chromosome ends.

In a 2003 study published in Bulletin of Experimental Biology and Medicine, Epithalon treatment of human fetal fibroblast cultures resulted in telomerase activation and extension of cell proliferative capacity beyond the Hayflick limit by 10 additional population doublings. A subsequent 2004 study demonstrated that Epithalon increased telomere length in peripheral blood lymphocytes of elderly patients from a mean of 7.41 kb to 8.34 kb over 12 months. However, these studies had small sample sizes (n=18-36) and have not been independently replicated in Western peer-reviewed journals.

MOTS-C (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded by the mitochondrial genome, discovered in 2015 by Changhan David Lee at the University of Southern California. With the sequence MRWQEMGYIFYPRKLR and a molecular weight of 2174.6 Da, MOTS-C is the first mitochondrial-encoded peptide shown to regulate nuclear gene expression — challenging the traditional view of mitochondria as passive organelles.

MOTS-C activates AMPK (5-AMP-activated protein kinase) and regulates the folate-methionine cycle, influencing cellular metabolism at a fundamental level. In mouse models, MOTS-C administration improved insulin sensitivity, reduced high-fat-diet-induced obesity, and enhanced exercise capacity. A 2020 study in Cell Metabolism demonstrated that exercise increases circulating MOTS-C levels in humans, with skeletal muscle identified as the primary target tissue. The peptide translocates to the nucleus under metabolic stress, directly regulating adaptive gene expression.

Humanin is a 24-amino-acid peptide (MW 2687.2 Da) encoded by the 16S rRNA region of mitochondrial DNA, first identified in 2001 through a functional screen for neuroprotective factors. Humanin and its analogs (HNG, S14G-Humanin) have demonstrated cytoprotective effects in cellular models of Alzheimer disease, oxidative stress, and apoptosis. The mechanism involves binding to IGFBP-3, modulating BAX-mediated apoptosis, and activating STAT3 signaling.

The small humanin-like peptides (SHLPs 1-6) were identified in 2016 as additional mitochondrial-derived peptides encoded in the same 16S rRNA region. SHLP2 and SHLP6 have shown distinct biological activities: SHLP2 promotes cell viability and mitochondrial metabolism, while SHLP6 induces apoptosis. Together, the humanin/SHLP family represents an emerging class of retrograde signaling molecules from mitochondria to the nucleus.

NAD+ (nicotinamide adenine dinucleotide) decline is a hallmark of aging, dropping approximately 50% between ages 40 and 60 in human tissue studies. While NMN and NR (small molecule precursors) address NAD+ decline through biosynthetic pathway supplementation, mitochondrial peptides intersect NAD+ metabolism differently. MOTS-C regulates the folate cycle, which feeds into one-carbon metabolism and indirectly influences NAD+ salvage pathway flux.

Humanin has been shown to upregulate NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in NAD+ biosynthesis, in hepatocyte models. This suggests that mitochondrial-derived peptides may support NAD+ homeostasis through enzymatic regulation rather than substrate provision — a mechanistically distinct approach from NMN/NR supplementation.

Senolytic compounds selectively eliminate senescent cells that accumulate with age and secrete inflammatory factors (SASP — senescence-associated secretory phenotype). While the leading senolytics are small molecules (dasatinib, quercetin, fisetin, navitoclax), peptide-based approaches are emerging. FOXO4-DRI, a modified peptide that disrupts the FOXO4-p53 interaction in senescent cells, demonstrated selective senescent cell clearance in aged mice in a 2017 Cell paper.

Epithalon research has shown reduced lipofuscin accumulation and beta-galactosidase activity (senescence markers) in treated cell cultures, suggesting indirect anti-senescence effects through telomere maintenance. However, direct senolytic activity — selective killing of senescent cells — has not been demonstrated for Epithalon, MOTS-C, or Humanin.

The clinical evidence base for longevity peptides varies substantially by compound. Epithalon has Phase II-equivalent data from Russian studies (n=266 combined) showing reduced mortality in elderly cohorts over 6-12 years of follow-up, but no FDA- or EMA-registered trials exist. MOTS-C has progressed to early clinical investigation for metabolic endpoints (NCT identifier pending as of 2026), driven by the USC research group. Humanin remains in preclinical stages with no registered human trials for aging endpoints.

• Epithalon: Phase II-equivalent (Russian studies only), no Western regulatory trials
• MOTS-C: Preclinical-to-early-clinical transition, metabolic endpoints
• Humanin/SHLP: Preclinical only, neuroprotection focus
• FOXO4-DRI: Single proof-of-concept in aged mice, no human data

Public interest in longevity peptides has been amplified by researchers such as David Sinclair (Harvard, NAD+ and epigenetic reprogramming) and clinicians such as Peter Attia (longevity medicine practice). While neither primarily researches peptides, their public discussions of aging biology have created broader awareness. Sinclair's 2019 book and Attia's 2023 book brought concepts like NAD+ decline, telomere biology, and mitochondrial dysfunction to mainstream audiences.

It is important to distinguish between the mechanistic research on these peptides — which is peer-reviewed and reproducible in laboratory settings — and the extrapolated health claims that circulate in longevity communities. The gap between in vitro gene expression changes and clinically meaningful lifespan extension remains substantial and largely unquantified as of 2026.

Research-grade longevity peptides require rigorous analytical verification. Epithalon (tetrapeptide): HPLC purity ≥98%, MS confirmation at m/z 391.4 [M+H]⁺. MOTS-C (16-mer): HPLC purity ≥95%, MS confirmation at m/z 2175.6 [M+H]⁺, amino acid analysis for sequence confirmation. Humanin (24-mer): HPLC purity ≥95%, requires sequence-specific MS/MS fragmentation. All should include endotoxin testing and reconstitution stability data.

• Khavinson VKh et al. (2003). Epithalon peptide and telomerase activation. Bull Exp Biol Med, 135(6):590-592.
• Khavinson VKh et al. (2004). Telomere length in elderly patients. Bull Exp Biol Med, 137(2):197-199.
• Lee C et al. (2015). MOTS-C: a mitochondrial-encoded peptide. Cell Metab, 21(3):443-454.
• Reynolds JC et al. (2020). MOTS-C is an exercise-induced mitochondrial peptide. Nat Commun, 12:595.
• Hashimoto Y et al. (2001). Humanin neuroprotective peptide discovery. Proc Natl Acad Sci USA, 98(11):6336-6341.
• Cobb LJ et al. (2016). Small humanin-like peptides. Aging Cell, 15(4):558-573.
• Baar MP et al. (2017). FOXO4-DRI senolytic peptide. Cell, 169(1):132-147.
• Sinclair DA, LaPlante MD. (2019). Lifespan: Why We Age. Atria Books.

Explore detailed chemical profiles and research guides for compounds discussed in this article:

• Epithalon: Complete Research Guide → /learn/epithalon
• Humanin: Complete Research Guide → /learn/humanin-research-guide-chemical-profile
• MOTS-C: Complete Research Guide → /learn/mots-c

• Read more: Khavinson Bioregulator Peptides: A Complete Scientific Overview → https://www.chemverify.com/learn/khavinson-bioregulator-peptides-scientific-overview
• Read more: Peptide Research for Hair Growth: GHK-Cu, PTD-DBM, and Copper Peptides → https://www.chemverify.com/learn/peptide-research-hair-growth-ghk-cu-copper
• Read more: Epithalon and Telomere Research: What the Science Actually Shows → https://www.chemverify.com/learn/epithalon-telomere-research-science-evidence
• Read more: Copper Peptides for Wound Healing Research: GHK-Cu Mechanism Deep Dive → https://www.chemverify.com/learn/copper-peptides-wound-healing-ghk-cu-mechanism